



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SECOND QUARTER					SIX MONTHS				
	2010	2009	% Change			2010	2009	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
CONSUMER SEGMENT ⁽²⁾										
SKIN CARE										
US	422	411	2.7%	2.7%	-	874	834	4.8%	4.8%	-
Intl	421	422	-0.2%	-0.5%	0.3%	889	841	5.7%	0.9%	4.8%
WW	843	833	1.2%	1.1%	0.1%	1,763	1,675	5.3%	2.9%	2.4%
BABY CARE										
US	99	104	-4.8%	-4.8%	-	202	206	-1.9%	-1.9%	-
Intl	438	404	8.4%	4.9%	3.5%	864	791	9.2%	3.1%	6.1%
WW	537	508	5.7%	2.9%	2.8%	1,066	997	6.9%	2.1%	4.8%
ORAL CARE										
US	148	174	-14.9%	-14.9%	-	322	362	-11.0%	-11.0%	-
Intl	224	212	5.7%	1.8%	3.9%	431	389	10.8%	3.3%	7.5%
WW	372	386	-3.6%	-5.8%	2.2%	753	751	0.3%	-3.6%	3.9%
OTC/NUTRITIONALS										
US	492	679	-27.5%	-27.5%	-	1,034	1,405	-26.4%	-26.4%	-
Intl	649	631	2.9%	1.9%	1.0%	1,314	1,253	4.9%	-0.5%	5.4%
WW	1,141	1,310	-12.9%	-13.4%	0.5%	2,348	2,658	-11.7%	-14.3%	2.6%
WOMEN'S HEALTH										
US	137	152	-9.9%	-9.9%	-	283	301	-6.0%	-6.0%	-
Intl	329	329	0.0%	-2.1%	2.1%	652	603	8.1%	2.4%	5.7%
WW	466	481	-3.1%	-4.5%	1.4%	935	904	3.4%	-0.4%	3.8%
WOUND CARE / OTHER										
US	165	188	-12.2%	-12.2%	-	308	326	-5.5%	-5.5%	-
Intl	123	148	-16.9%	-20.3%	3.4%	240	254	-5.5%	-11.4%	5.9%
WW	288	336	-14.3%	-15.8%	1.5%	548	580	-5.5%	-8.1%	2.6%
TOTAL CONSUMER										
US	1,463	1,708	-14.3%	-14.3%	-	3,023	3,434	-12.0%	-12.0%	-
Intl	2,184	2,146	1.8%	-0.2%	2.0%	4,390	4,131	6.3%	0.6%	5.7%
WW	3,647	3,854	-5.4%	-6.5%	1.1%	7,413	7,565	-2.0%	-5.1%	3.1%

* See footnotes on page 3

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SECOND QUARTER					SIX MONTHS				
	2010	2009	% Change			2010	2009	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
PHARMACEUTICAL SEGMENT ^{(2) (6)}										
ACIPHEX/PARIET										
US	121	128	-5.5%	-5.5%	-	240	266	-9.8%	-9.8%	-
Intl	133	132	0.8%	2.1%	-1.3%	274	257	6.6%	2.7%	3.9%
WW	254	260	-2.3%	-1.6%	-0.7%	514	523	-1.7%	-3.6%	1.9%
CONCERTA										
US	223	233	-4.3%	-4.3%	-	454	502	-9.6%	-9.6%	-
Intl	100	84	19.0%	16.3%	2.7%	198	159	24.5%	16.7%	7.8%
WW	323	317	1.9%	1.2%	0.7%	652	661	-1.4%	-3.3%	1.9%
DURAGESIC/FENTANYL TRANSDERMAL										
US	37	50	-26.0%	-26.0%	-	75	125	-40.0%	-40.0%	-
Intl	147	168	-12.5%	-12.6%	0.1%	293	324	-9.6%	-13.1%	3.5%
WW	184	218	-15.6%	-15.7%	0.1%	368	449	-18.0%	-20.5%	2.5%
LEVAQUIN/FLOXIN										
US	289	343	-15.7%	-15.7%	-	652	751	-13.2%	-13.2%	-
Intl	11	19	-42.1%	-44.8%	2.7%	19	36	-47.2%	-50.2%	3.0%
WW	300	362	-17.1%	-17.2%	0.1%	671	787	-14.7%	-14.8%	0.1%
PREZISTA										
US	99	65	52.3%	52.3%	-	188	137	37.2%	37.2%	-
Intl	105	75	40.0%	42.1%	-2.1%	203	125	62.4%	57.3%	5.1%
WW	204	140	45.7%	46.8%	-1.1%	391	262	49.2%	46.8%	2.4%
PROCRI/EPREX										
US	306	330	-7.3%	-7.3%	-	596	651	-8.4%	-8.4%	-
Intl	220	247	-10.9%	-9.3%	-1.6%	453	476	-4.8%	-7.8%	3.0%
WW	526	577	-8.8%	-8.1%	-0.7%	1,049	1,127	-6.9%	-8.2%	1.3%
REMICADE										
US	783	771	1.6%	1.6%	-	1,563	1,508	3.6%	3.6%	-
US Exports ⁽³⁾	341	327	4.3%	4.3%	-	741	613	20.9%	20.9%	-
Intl	6	4	50.0%	50.0%	-	12	9	33.3%	33.2%	0.1%
WW	1,130	1,102	2.5%	2.5%	-	2,316	2,130	8.7%	8.7%	-
RISPERDAL/RISPERIDONE										
US	(17)	70	-124.3%	-124.3%	-	(12)	188	-106.4%	-106.4%	-
Intl	134	169	-20.7%	-22.1%	1.4%	267	326	-18.1%	-21.2%	3.1%
WW	117	239	-51.0%	-52.0%	1.0%	255	514	-50.4%	-52.4%	2.0%
RISPERDAL CONSTA										
US	115	131	-12.2%	-12.2%	-	232	257	-9.7%	-9.7%	-
Intl	240	217	10.6%	12.8%	-2.2%	502	416	20.7%	16.9%	3.8%
WW	355	348	2.0%	3.4%	-1.4%	734	673	9.1%	6.8%	2.3%
TOPAMAX										
US	59	75	-21.3%	-21.3%	-	116	570	-79.6%	-79.6%	-
Intl	83	107	-22.4%	-21.4%	-1.0%	174	214	-18.7%	-21.6%	2.9%
WW	142	182	-22.0%	-21.4%	-0.6%	290	784	-63.0%	-63.8%	0.8%
VELCADE										
US	-	-	-	-	-	-	-	0.0%	0.0%	-
Intl	286	229	24.9%	25.1%	-0.2%	547	421	29.9%	25.8%	4.1%
WW	286	229	24.9%	25.1%	-0.2%	547	421	29.9%	25.8%	4.1%
OTHER										
US	754	649	16.2%	16.2%	-	1,471	1,278	15.1%	15.1%	-
Intl	978	875	11.8%	10.3%	1.5%	1,933	1,669	15.8%	10.5%	5.3%
WW	1,732	1,524	13.6%	12.8%	0.8%	3,404	2,947	15.5%	12.5%	3.0%
TOTAL PHARMACEUTICAL										
US	3,110	3,172	-2.0%	-2.0%	-	6,316	6,846	-7.7%	-7.7%	-
Intl	2,443	2,326	5.0%	4.9%	0.1%	4,875	4,432	10.0%	5.7%	4.3%
WW	5,553	5,498	1.0%	1.0%	0.0%	11,191	11,278	-0.8%	-2.5%	1.7%
MAJOR NEW PHARM PRODUCTS ⁽⁴⁾										
INVEGA										
US	68	67	1.5%	1.5%	-	137	133	3.0%	3.0%	-
Intl	34	32	6.3%	8.3%	-2.0%	73	57	28.1%	23.8%	4.3%
WW	102	99	3.0%	3.6%	-0.6%	210	190	10.5%	9.2%	1.3%

* See footnotes on page 3

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SECOND QUARTER					SIX MONTHS				
	2010	2009	% Change			2010	2009	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
MEDICAL DEVICES AND DIAGNOSTICS ⁽²⁾										
<u>CORDIS ⁽⁵⁾</u>										
US	265	252	5.2%	5.2%	-	516	498	3.6%	3.6%	-
Intl	390	422	-7.6%	-8.6%	1.0%	811	844	-3.9%	-7.4%	3.5%
WW	655	674	-2.8%	-3.4%	0.6%	1,327	1,342	-1.1%	-3.3%	2.2%
<u>DEPUY</u>										
US	776	762	1.8%	1.8%	-	1,590	1,528	4.1%	4.1%	-
Intl	599	561	6.8%	6.0%	0.8%	1,239	1,087	14.0%	8.5%	5.5%
WW	1,375	1,323	3.9%	3.5%	0.4%	2,829	2,615	8.2%	5.9%	2.3%
<u>DIABETES CARE</u>										
US	313	306	2.3%	2.3%	-	603	576	4.7%	4.7%	-
Intl	303	304	-0.3%	1.1%	-1.4%	610	575	6.1%	3.2%	2.9%
WW	616	610	1.0%	1.7%	-0.7%	1,213	1,151	5.4%	4.0%	1.4%
<u>ETHICON</u>										
US	509	452	12.6%	12.6%	-	1,019	857	18.9%	18.9%	-
Intl	623	589	5.8%	5.0%	0.8%	1,260	1,137	10.8%	6.1%	4.7%
WW	1,132	1,041	8.7%	8.2%	0.5%	2,279	1,994	14.3%	11.6%	2.7%
<u>ETHICON ENDO-SURGERY</u>										
US	507	489	3.7%	3.7%	-	990	943	5.0%	5.0%	-
Intl	689	626	10.1%	8.8%	1.3%	1,374	1,187	15.8%	10.7%	5.1%
WW	1,196	1,115	7.3%	6.6%	0.7%	2,364	2,130	11.0%	8.2%	2.8%
<u>ORTHO-CLINICAL DIAGNOSTICS</u>										
US	264	284	-7.0%	-7.0%	-	552	561	-1.6%	-1.6%	-
Intl	230	210	9.5%	8.4%	1.1%	467	400	16.8%	12.2%	4.6%
WW	494	494	0.0%	-0.5%	0.5%	1,019	961	6.0%	4.1%	1.9%
<u>VISION CARE</u>										
US	232	231	0.4%	0.4%	-	481	465	3.4%	3.4%	-
Intl	430	399	7.8%	3.9%	3.9%	845	764	10.6%	5.4%	5.2%
WW	662	630	5.1%	2.6%	2.5%	1,326	1,229	7.9%	4.6%	3.3%
TOTAL MEDICAL DEVICES AND DIAGNOSTICS										
US	2,865	2,776	3.2%	3.2%	-	5,751	5,428	6.0%	6.0%	-
Intl	3,265	3,111	5.0%	3.9%	1.1%	6,606	5,994	10.2%	5.6%	4.6%
WW	6,130	5,887	4.1%	3.5%	0.6%	12,357	11,422	8.2%	5.8%	2.4%

⁽¹⁾ Operational growth excludes the effect of currency

⁽²⁾ Select areas (unaudited)

⁽³⁾ Reported in U.S. sales

⁽⁴⁾ Included in Other

⁽⁵⁾ Includes sales of Drug-Eluting Stents for Q2 2010 of \$59, \$108 and \$167MM Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for Q2 2009 of \$69, \$165 and \$234MM Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for June YTD 2010 of \$119, \$238 and \$357MM Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for June YTD 2009 of \$136, \$349 and \$485MM Domestic, International and Worldwide respectively

⁽⁶⁾ Conforms to current presentation